Endogest

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Endogest

Property Description
Active Ingredient Natural Micronised Progesterone; or Combination (Amylase, Diastase, Ca Carbonate, Scopolia Extr, Vit B1)
Primary Form Capsule (Soft Gelatin), Tablet (often Sustained-Release)
Pharmacological Class Progestin Hormone; or Combination Digestive Enzyme and Antacid
Origin Natural (Progesterone is plant-derived, chemically identical to human hormone)
Route of Admin. Oral, Vaginal

What Type of Medicine is Endogest? (Definition and Classification)

Endogest is primarily recognized as a prescription hormonal agent belonging to the progestin pharmacological class, formulated using Natural Micronised Progesterone. The active component, Progesterone, is chemically identical to the hormone produced endogenously and is synthesized from a plant source material. This hormonal formulation is clinically recognized for its role in hormone replacement therapy and gynecological support, distinguishing it from older, synthetic progestin analogues.

However, the trade name Endogest is also associated in some regions with a separate combination product used as a digestive and nutritional aid. This distinct classification—either a single-entity hormone or a multi-component blend—requires careful identification of the specific product based on its full composition.

Endogest Composition and Available Forms (Ingredients and Pharmaceutical Identity)

The dominant formulation centers on Progesterone, which undergoes micronisation—a process that reduces particle size to enhance the substance's absorption and overall bioavailability when administered. The alternative, multi-component product is a fixed-dose combination of digestive enzymes (Amylase, Diastase), antacids (Calcium Carbonate, Sodium Bicarbonate), the mild antispasmodic Scopolia Extract, and the essential nutrient Vitamin B1. Endogest is supplied as capsules (often soft gelatin) and tablets, including specialized Sustained-Release (SR) tablets, which allows it to be administered via oral or vaginal routes, providing a key factor in flexible patient care.

General Purpose: What Does Endogest Help To Do? (High-Level Mechanism and Benefit)

The general purpose of the Progesterone formulation is to help manage hormonal imbalance by providing essential hormone replacement and support for the uterine lining. By supplying the progestin hormone, it assists the body in restoring or supporting key cyclical processes. Conversely, the multi-component formulation is purposed for supporting gastrointestinal function: its combined action helps the body efficiently process nutrients through enzyme supplementation and helps manage hyperacidity through gastric acid neutralization.

Regulatory References

  1. Progesterone Capsule Label
  2. Progesterone Oral: MedlinePlus Drug Information

What side effects are possible with Endogest?

Possible Side Effects and Safety Information

Regulatory safety documents classify the adverse reactions associated with Endogest (micronized progesterone) by how often they appear and the body systems they affect. These classifications strictly adhere to the standards used by government health authorities.

Frequency-Classified Adverse Reactions

The most commonly listed side effects predominantly involve the nervous and gastrointestinal systems, often observed during the initial phases of therapy.

  • Very Common (mathbfge 10%): Headache, abdominal pain, somnolence (drowsiness), breast tenderness/pain, depression, and abdominal bloating.
  • Common (mathbfge 1% to <mathbf10%): Dizziness, nausea, insomnia, fatigue, joint pain, diarrhea, and intermenstrual bleeding/spotting.
  • Uncommon (mathbfge 0.1% to <mathbf1%): Urticaria (hives), abnormal liver function tests, and visual disturbances.

Serious Adverse Reactions and Safety Constraints

The official label documents several serious adverse reactions, primarily noted in the context of the medication's use as a component of Hormone Replacement Therapy (HRT). These include an associated risk of Venous Thromboembolism (VTE), Stroke, and Breast Cancer when used long-term in combination with estrogen.

Safety restrictions are also defined. The medication should not be used in individuals with a history of active thromboembolic disorders, undiagnosed genital bleeding, estrogen-dependent malignant tumors, or severe hepatic dysfunction. Certain capsule formulations contain soybean lecithin, which is noted as a safety consideration for individuals with a known peanut or soya allergy.

Overdose and Emergency Response

Overdose and When to Seek Help: Endogest (Progesterone)

The official regulatory profile for progesterone (Endogest) overdose focuses on managing expected symptoms, as serious ill effects are generally not reported following acute ingestion.

Documented Overdose Manifestations

Symptoms of taking too much Endogest are typically an extension of common side effects, primarily affecting the central nervous system (CNS) and hormonal systems. Official documents list the following signs:

  • CNS Effects: Drowsiness, sleepiness, dizziness, lightheadedness, tiredness, or a depressive mood.
  • Other Effects: Nausea and vomiting.
  • Hormonal Effects: Withdrawal bleeding (in females).

Immediate Actions and Emergency Care

Regulatory agencies instruct patients to seek immediate medical guidance upon suspicion of an overdose. The primary actions required are:

  • Seek Help Immediately: Contact a Poison Control Center or Emergency Room at once. If located outside the United States, consult a doctor or emergency medical service immediately.
  • Official Treatment: Treatment consists of discontinuation of the drug followed by the institution of appropriate symptomatic and supportive care.
  • Antidote: No specific antidote is listed or required; management focuses on treating the clinical manifestations present.

This information is based strictly on authoritative government regulatory documents, defining the overdose risk as low-severity with mandated immediate medical consultation.

Therapeutic Uses of Endogest

Quick Facts

  • May be used to assist in addressing: The absence of menstrual periods (amenorrhea).
  • May be used to assist in addressing: Abnormal thickening of the uterine lining (endometrial hyperplasia) in certain contexts.
  • May be used to assist in addressing: Conditions related to assisted reproductive technology (ART) programs.

What Endogest Treats: Main Uses and Benefits

Endogest is a prescription medication that contains micronized progesterone, a substance that is chemically identical to a naturally occurring female hormone. The use of this preparation is associated with several therapeutic indications related to a lack of this hormone in the body.

This medication is primarily indicated for assisting in the management of two gynecologic conditions. Firstly, it may be used to help bring about a menstrual period in non-pregnant women who have experienced the cessation of menstruation (secondary amenorrhea). Secondly, it is prescribed as a component of hormone replacement therapy (HRT) to help mitigate the risk of abnormal thickening of the lining of the uterus (endometrial hyperplasia) in women taking estrogen therapy.

Furthermore, the use of this progesterone formulation may provide support for the luteal phase as part of certain assisted reproductive technology (ART) treatment protocols.

Eligibility and Restrictions for Use

Who Can and Cannot Use Endogest (Micronized Progesterone)

Official regulatory documents define strict criteria for the population eligible to use Endogest, a medicine containing micronized progesterone. These criteria classify users into those who are absolutely prohibited from using the drug (Contraindicated), those for whom use is permitted under monitoring (Restricted Use), and those for whom use is not established (Not Indicated).


Absolute Contraindications

Use of Endogest is strictly prohibited in patients with certain conditions, including:

  • A history of arterial or venous thromboembolism (blood clots).
  • Known or suspected breast cancer or other hormone-sensitive malignancies.
  • Severe hepatic (liver) disease or dysfunction.
  • Undiagnosed abnormal genital bleeding.
  • Known hypersensitivity to progesterone or product components (e.g., peanut oil in some oral forms).

Restricted and Age-Based Use

Population Group Regulatory Status Restriction Basis
Pediatric Use Not Indicated Safety and efficacy have not been established.
Renal Impairment Use with Caution Requires careful monitoring due to metabolite clearance.
Pregnancy Indication-Specific Only used for specific labeled purposes, such as Luteal Support in ART.

Patients with a history of depression, epilepsy, or asthma are eligible but must be closely monitored during treatment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Endogest is defined by its metabolism through the cytochrome P450 (CYP) enzyme system, specifically CYP3A4, and its own potential to inhibit this enzyme. These pharmacokinetic interactions can significantly alter the exposure of either Endogest or co-administered medicines.

Potential Drug-Drug Interactions

Interacting Product Category Effect on Endogest Exposure Practical Implication (Regulatory)
Strong CYP3A4 Inducers (e.g., rifampin, St. John's wort) Substantially decreased exposure Use is generally advised against, or requires close clinical monitoring and potential dose increase.
Strong CYP3A4 Inhibitors (e.g., ketoconazole, clarithromycin) Substantially increased exposure Requires close monitoring for adverse effects and potential dose reduction.
CYP3A4 Substrates (e.g., simvastatin, midazolam) Increased substrate exposure Endogest can inhibit CYP3A4, requiring caution and possible dosage adjustment for the co-medication.

Specific High-Risk Combinations

Official regulatory information highlights a specific interaction with Warfarin and other oral anticoagulants. Coadministration is associated with potential risks. For patients requiring anticoagulation, substitution of oral anticoagulants with low-molecular-weight or standard heparin is officially recommended to manage this documented interaction risk. Always consult a healthcare professional regarding all medicines and supplements currently being taken.

Mechanism of Action

Endogest provides micronized progesterone, a steroid hormone that acts as a potent agonist for the ubiquitous intracellular progesterone receptors (PRs), including isoforms PR-A and PR-B. Upon binding to the ligand-binding domain in the cytoplasm, the progesterone-PR complex dissociates from chaperone proteins, undergoes dimerization, and translocates into the nucleus.

In the nucleus, the dimer functions as a ligand-activated transcription factor, binding to specific Progestin Response Elements (PREs) in the promoter regions of target genes. This genomic interaction modulates the expression of genes responsible for key cellular processes, specifically inducing the secretory transformation of the endometrium and suppressing its mitotic activity. Progesterone also exhibits rapid, non-genomic actions via membrane-associated PRs, activating intracellular signaling cascades like the MAPK/ERK pathway. At the system level, this modulation of gene expression and cellular signaling supports endometrial differentiation, reduces uterine smooth muscle contractility, and exerts negative feedback on pituitary gonadotropin secretion (Luteinizing Hormone), thereby regulating the endocrine environment.

Dosage and Administration Information

Endogest, a formulation containing Natural Micronised Progesterone, is administered according to specific guidelines. The approved route of administration is determined by the treatment regimen, utilizing either oral capsules or specialized vaginal forms.


Official Administration Guidelines

Instruction Category Protocol Summary
Dosing Schedule Doses are prescribed based on the condition. This ranges from 200 mg daily for 12 continuous days per cycle (for endometrial protection) to 400 mg daily for a 10-day course (for secondary amenorrhea). Vaginal regimens for reproductive support are typically 100 mg to 200 mg taken multiple times per day.
Frequency and Timing Oral dosages are taken once daily as a single dose. This dose must be administered at bedtime and generally with food to optimize absorption. Vaginal administration is often prescribed in two or three divided doses throughout the day.
Preparation Requirements Oral capsules must be swallowed whole and should not be crushed, chewed, or divided to maintain the intended release profile. Vaginal forms should be inserted deep using the provided applicator.
Course Duration Use is strictly defined as a cyclic regimen (e.g., 12 days on per month) or as a finite course, such as the 10-day course for amenorrhea or up to 10-12 weeks total duration for luteal phase support.

Connection to the overall use protocol: These official instructions establish a precise use protocol that governs the administration route, required milligram strength, and a clear, non-negotiable timeframe of use. Following these specifications ensures the medicine is utilized exactly as intended.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Endogest

The available research for the Endogest formulation containing Natural Micronised Progesterone comes primarily from controlled clinical trials, systematic reviews, and meta-analyses. These studies are designed to explore how the medicine was studied for specific women's health contexts. The summary below describes the structure of the evidence and what researchers have studied, without giving advice or predicting individual results.


Evidence for Use in Restoring Menstrual Cycles (Secondary Amenorrhea)

Research examined how the medicine was studied in women whose menstrual cycles stopped due to a lack of progesterone. The primary outcomes studied included the re-establishment of menses and whether a withdrawal bleed occurred. The findings describe patterns observed in the studies where treatment was evaluated in defined time intervals. What remains uncertain is the extent of long-term data; there is limited information for long-term outcomes following repeated or continuous use.


Evidence for Uterine Lining Protection in HRT (Endometrial Hyperplasia)

Studies research examined the practice of adding progesterone to estrogen therapy in postmenopausal women with an intact uterus, focusing on the measurement of the incidence of endometrial hyperplasia (abnormal uterine lining thickening). Findings indicate that when used alongside estrogen, research explored outcomes related to the uterine lining when receiving estrogen therapy. The independent role of progesterone alone is not universally established across all major trials, and comparative evidence is lacking for long-term safety against synthetic progestins.


Evidence for Luteal Phase Support in Assisted Reproduction Technology (ART)

Research in this area includes a large body of randomized controlled trials (RCTs) and meta-analyses. Studies explored key reproductive outcomes, including measured rates of ongoing pregnancy, clinical pregnancy, and live birth. However, findings were mixed regarding the optimal dose and the best route of administration (oral versus vaginal) required to maintain consistent hormone levels. Research is ongoing to standardize protocols.


Core Research Gaps and Uncertainty

The evidence highlights what is known — and what is still uncertain across all areas of research. A key research gap is the continued debate around optimal dose and route of administration (oral vs. vaginal), particularly for luteal phase support in ART. Furthermore, long-term effects are not fully established for all uses, meaning findings describe group patterns, not personal outcomes several years after treatment conclusion.

Key Studies & References

  1. Progesterone Capsules (Micronized) Official Prescribing Information – DailyMed
  2. Progesterone (Oral Route) Drug Information – MedlinePlus

Frequently Asked Questions (FAQ)

Common questions about Endogest (FAQ)

Q: How quickly should I expect to feel the effects of Endogest?

Official regulatory information on the oral capsule indicates that the active ingredient is generally observed to reach peak concentrations in the blood within approximately three hours of administration. However, the regulatory label does not specify how soon a user should expect to 'feel' the therapeutic effects of the medicine.

Q: Can taking Endogest affect my mood or make me feel tired?

Yes, official safety documents list side effects that can affect mood and energy. Somnolence (drowsiness) and fatigue are commonly reported. Additionally, mood changes, including the experience of depression or mood swings, have been noted. Due to the risk of drowsiness, the official guidance for the oral form recommends administration at bedtime.

Q: What is the difference between Endogest and Prometrium?

Regulatory documents confirm that Endogest is a formulation of Natural Micronised Progesterone. The drug Prometrium is also a formulation of micronized progesterone, USP. Official information states that the active ingredient in both is chemically identical to the hormone naturally produced by the human body.

Q: Can men ever be prescribed Endogest for any condition?

The official indications for this medication are specific to women's health concerns, such as amenorrhea or hormone replacement therapy. While studies sometimes use male volunteers to understand how the drug is absorbed and metabolized, this does not establish approval or indication for its use in men, as the labeled indications are specific to women’s health.

Q: Is it common for Endogest users to feel bloated?

Yes, regulatory safety documents classify abdominal bloating as a Very Common side effect, meaning it is reported in 10% or more of patients during clinical trials. This is a common occurrence reported in trials, especially during the initial phases of therapy.

Q: Is Endogest used to treat symptoms of menopause?

Endogest is officially indicated for use as part of Hormone Replacement Therapy (HRT) for postmenopausal women who have an intact uterus. Its purpose in this context is to protect the uterine lining. The regulatory label does not state that it is used to directly treat general symptoms of menopause, such as hot flashes.

Q: Does Endogest affect liver function in the long term?

Official safety constraints state that severe hepatic (liver) disease or dysfunction is an absolute contraindication for use. Regulatory warnings advise caution, with some formulations noting abnormal liver function tests as an uncommon side effect. However, the official documents state that long-term data for this specific area is limited or not established for otherwise healthy users.

Q: Can Endogest cause headaches or migraines?

Headache is listed as a Very Common side effect in safety documents. Furthermore, more severe forms of headache, such as migraines, have also been reported in official safety documents, though these are typically listed as less common.

Q: Does Endogest affect the results of blood tests?

Official information indicates that the use of progestins can influence the results of certain laboratory tests. For example, progestins can influence the results of certain laboratory tests, such as those measuring clotting factors or levels of thyroid-binding globulin.

Q: Are allergic reactions to Endogest common, and what are the signs?

A known hypersensitivity to progesterone or any component (such as the presence of peanut oil in some oral forms) is a contraindication. The official documents list Urticaria (hives) as an Uncommon side effect. Any sign of a severe allergic reaction warrants immediate contact with a healthcare professional.

Q: Why is the timing of taking Endogest often emphasized by doctors?

The official instructions for the oral capsule emphasize taking the dose at bedtime. This is primarily due to the very common side effect of somnolence (drowsiness), which taking it at night can help mitigate. Official guidance also specifies that the oral dose should be taken with food to ensure optimal drug absorption.

Q: Can Endogest be used for people who have had a hysterectomy?

Regulatory documents state that Endogest is indicated for use in combination with estrogen in postmenopausal women with an intact uterus. The official label does not specifically address or indicate its use for women who have undergone a hysterectomy.

Q: Are there known long-term risks associated with taking Endogest?

When used long-term specifically in combination with estrogen as part of HRT, the regulatory label documents associated risks including Venous Thromboembolism (VTE), Stroke, and Breast Cancer. However, the official evidence also notes that the long-term effects for all uses are not fully established.

Q: Do certain medications for depression or anxiety interact with Endogest?

The official interaction profile is defined by the CYP3A4 enzyme system, which processes the medicine in the body. If a medication for depression or anxiety is a strong CYP3A4 inducer or inhibitor, a pharmacokinetic interaction that could alter the level of Endogest in the blood is possible. The official label does not list all specific psychotropic drugs.

Q: Can Endogest affect sleep patterns?

Yes, according to safety documents, adverse reactions related to sleep are documented. These include both somnolence (drowsiness), which is very common, and insomnia (difficulty sleeping), which is listed as a common side effect.

Q: Will Endogest interfere with other hormonal therapies?

Regulatory documents indicate that Endogest can act as an enzyme inhibitor, which has the potential to increase the exposure of other co-administered medications that are processed by the same enzyme system ( CYP3A4). For this reason, caution is advised and possible dosage adjustment for the co-medication should be discussed with a prescriber.

Q: Why do some people experience breast tenderness with Endogest?

Breast tenderness/pain is classified as a Very Common side effect of this medication. This is generally attributed to the drug's action as a hormonal agent. However, the official regulatory label does not explain the precise cellular mechanism for this specific symptom.

Q: Can Endogest be prescribed to teenagers?

Official regulatory documents explicitly state that the medication is Not Indicated for pediatric use, which indicates that its safety and efficacy for the pediatric population have not been established.

Q: Do I need a special diet while I am taking Endogest?

The official guidelines for the oral capsule state that it should be administered with food to achieve optimal absorption. However, the official prescribing information does not mandate a special diet (such as low-fat or high-fiber).

Q: Does Endogest carry a risk of birth defects if taken during pregnancy (when not prescribed for it)?

The drug is indicated for use only for specific, labeled purposes in early pregnancy, such as Luteal Support in ART. Outside of this labeled use, the product forms are generally subject to warnings, as there is inadequate data to fully inform a drug-related risk to the fetus.

Q: Are there any specific medical screening tests required before starting Endogest?

The regulatory label requires patients to be evaluated for absolute contraindications like a history of blood clots or liver dysfunction. Regulatory documents generally advise that patients receiving progesterone therapy should undergo regular physical and breast examinations.

Q: What should I do if the side effects of Endogest become bothersome?

Official regulatory documents advise discussing any bothersome side effects with a doctor or pharmacist. It is also important to consult a healthcare professional immediately if a serious adverse reaction occurs or is suspected.

Q: How long does Endogest stay in your system after stopping the medication?

The half-life (the time it takes for the concentration of the drug in the blood to decrease by half) is generally reported in regulatory documents to be approximately 5 to 10 hours for the oral capsule. This pharmacokinetic information determines how quickly the medicine is cleared from the body.

Q: Can Endogest be used to help regulate menstrual cycles?

Endogest is specifically indicated for the treatment of secondary amenorrhea (the absence of menstrual periods) in women who have previously had menses, which works by restoring a menstrual cycle through a withdrawal bleed. It is not generally indicated in official documents for the broader purpose of 'regulating' all menstrual cycle irregularities.

How should Endogest be stored and disposed of?

How to Store and Dispose of Endogest (Progesterone)

Official regulatory information mandates specific conditions for storing and disposing of Endogest to maintain product stability and safety.

Official Storage Requirements

Condition Requirement (Label-Based)
Temperature Store at 20-25 C ( 68-77 F) (Controlled Room Temperature).
Protection Protect from excessive heat, moisture, and light.
Container Keep medication in the original container, tightly closed.
Access Must be stored out of the reach of children.

Disposal Instructions

To ensure proper disposal, do not flush unused or expired Endogest down the toilet or throw it in the household trash unless specifically instructed by official medication take-back programs. Discard any unused product or waste material after the expiration date according to local pharmaceutical disposal guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Endogest found in:

A-Z Index: